Phase II study of accelerated fractionation radiation therapy with carboplatin followed by PCV chemotherapy for the treatment of anaplastic gliomas

International Journal of Radiation Oncology Biology Physics

Volumn 53, Issue 1, 2002, Pages 58-66

  Levin, V A ^a,b   Yung, W K A ^a   Bruner, J ^a   Kyritsis, A ^a   Leeds, N ^a   Gleason, M J ^a   Hess, K R ^a   Meyers, C A ^a   Ictech, S A ^a   Chang, E ^a   Maor, M H ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b UNIVERSITY OF TEXAS   (United States)

Author keywords

Accelerated fractionated radiotherapy; Anaplastic astrocytoma; Anaplastic oligoastrocytoma; Anaplastic oligodendroglioma; Carboplatin; PCV

Indexed keywords

BIOPSY; BRAIN; CHEMOTHERAPY; MAGNETIC RESONANCE IMAGING; NEUROLOGY; SURGERY; TOXICITY; TUMORS;

ANAPLASTIC GLIOMAS;

RADIOTHERAPY;

CARBOPLATIN; LOMUSTINE; PROCARBAZINE; VINCRISTINE;

ADULT; AGE; AGED; ARTICLE; ASTROCYTOMA; BRAIN NECROSIS; CANCER ADJUVANT THERAPY; CANCER RADIOTHERAPY; CANCER SURGERY; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEMENTIA; FEMALE; GLIOBLASTOMA; GLIOMA; HISTOLOGY; HUMAN; MAJOR CLINICAL STUDY; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; OLIGODENDROGLIOMA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGNOSIS; RADIATION DOSE; RADIATION NECROSIS; REOPERATION; SURVIVAL RATE; TUMOR BIOPSY; TUMOR GROWTH;

ADOLESCENT; ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; ASTROCYTOMA; BRAIN NEOPLASMS; CARBOPLATIN; COMBINED MODALITY THERAPY; DOSE FRACTIONATION; FEMALE; HUMANS; LOMUSTINE; MALE; MIDDLE AGED; OLIGODENDROGLIOMA; PROCARBAZINE; SURVIVAL ANALYSIS; VINCRISTINE;

EID: 0036569653     PISSN: 03603016     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0360-3016(01)02819-X     Document Type: Article

References (33)

1. Superiority of post-radiotherapy adjuvant chemotherapy with CCNU, procarbazine, and vincristine PCV) over BCNU for anaplastic gliomas: NCOG 6G61 final report
2. Phase II study of accelerated fractionation radiation therapy with carboplatin followed by vincristine chemotherapy for the treatment of glioblastoma multiforme
3. Modification of the effects of continuous low dose rate irradiation by concurrent chemotherapy infusion
4. The influence of time sequence of cisplatin administration and continuous low dose rate irradiation (CLDRI) on their combined effects on a murine squamous cell carcinoma
5. Carboplatin as a potentiator of radiation therapy
6. Cisplatin in the treatment of recurrent childhood primary brain tumors
7. Intravenous carboplatin for recurrent malignant gliomas: A phase II study
8. Criteria for evaluating patients undergoing chemotherapy for malignant brain tumors
9. Evaluation of bromodeoxyuridine in glioblastoma multiforme: A Northern California Cancer Center Phase II study
10. Sample size considerations for studies comparing survival curves using historical controls
11. Nonparametric estimates from incomplete observations
12. Regression models and life tables
13. Radiation therapy and hydroxyurea followed by the combination of 6-thioguanine and BCNU for the treatment of primary malignant brain tumors
14. A phase 3 randomized study of radiotherapy plus procarbazine, CCNU, and vincristine (PCV) with or without BUdR for the treatment of anaplastic astrocytoma: A preliminary report of RTOG 9404
15. Radiation therapy and bromodeoxyuridine chemotherapy followed by procarbazine, lomustine, and vincristine for the treatment of anaplastic gliomas
16. Malignant gliomas: MR imaging spectrum of radiation therapy- and chemotherapy-induced necrosis of the brain after treatment
17. Increasing radiation dose intensity using hyperfractionation in patients with malignant glioma. Final report of a prospective Phase I-II dose response study
18. External irradiation followed by an interstitial high activity iodine- 125 implant "boost" in the initial treatment of malignant gliomas: NCOG study 6G-82-2
19. Radiosurgery as part of the initial management of patients with malignant gliomas
20. Combination of radiotherapy and drugs for the treatment of malignant gliomas
21. Radiation therapy for neoplasms of the brain
22. Neoplasms of the central nervous system
23. Cerebral radio-necrosis: Incidence and risk in relation to dose, time, fractionation and volume
24. White matter changes are correlated significantly with radiation dose. Observations from a randomized dose-escalation trial for malignant glioma (Radiation Therapy Oncology Group 83-02)
25. Radiation therapy and bromodeoxyuridine chemotherapy followed by procarbazine, lomustine, and vincristine for the treatment of anaplastic gliomas
26. Advantage of post-radiotherapy chemotherapy with CCNU, procarbazine, and vincristine (mPCV) over chemotherapy with VM-26 and CCNU for malignant gliomas
27. Current treatment of oligodendrogliomas
28. Neoadjuvant procarbazine, CCNU, and vincristine for anaplastic and aggressive oligodendroglioma
29. Oligodendroglioma. An analysis of prognostic factors and treatment results
30. Different risks of symptomatic brain necrosis in NPC patients treated with different altered fractionated radiotherapy techniques
31. Phase III comparative evaluation of PCNU and carmustine combined with radiation therapy for high-grade glioma